Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: Preliminary data

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 8, 2001, Pages 619-625

  Wade, W E ^a   Spruill, W J ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Cost effectiveness; Spinal cord injury; Thromboembolism

Indexed keywords

ENOXAPARIN; TINZAPARIN; FIBRINOLYTIC AGENT; HEPARIN, LOW MOLECULAR WEIGHT; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SPINAL CORD INJURY; THROMBOEMBOLISM; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; INFORMATION PROCESSING; LUNG EMBOLISM; PHARMACOKINETICS; STANDARD; VEIN THROMBOSIS;

COMPARATIVE STUDY; COST-BENEFIT ANALYSIS; DATA COLLECTION; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; PULMONARY EMBOLISM; SPINAL CORD INJURIES; THERAPEUTIC EQUIVALENCY; VENOUS THROMBOSIS;

EID: 0035205958     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200112000-00002     Document Type: Article

References (63)

1. The prophylactic use of anticoagulant therapy in the prevention of pulmonary embolism in 100 consecutive spinal injury patients
2. Deep venous thrombosis in spinal cord injury: Overview of the problem
3. Venous thrombosis in acute spinal cord paralysis
4. Systematic low limb phlebography in acute spinal cord injury in 147 patients
5. Fibrinolysis and spinal injury: Relationship to post-traumatic deep vein thrombosis
6. Etiology, incidence, and prevention of deep vein thrombosis in acute spinal cord injury
7. Deep vein thrombosis in spinal cord injured patients
8. Sequential changes in factor VIII and platelets preceding deep vein thrombosis in patients with spinal cord injury
9. A prospective study of venous thromboembolism after major trauma
10. Deep vein thrombosis: Prophylaxis in acute spinal cord injured patients
11. Deep venous thrombosis and pulmonary embolism in patients with acute spinal cord injury: A comparison with nonparalyzed patients immobilized due to spinal fractures
12. Deep vein thrombosis in spinal cord injury: Effect of prophylaxis with calf compression, aspirin and dipyridamole
13. Prevention of thromboembolism after spinal cord injury using low-molecular weight heparin
14. Prevalence of deep vein thrombosis in patients with chronic spinal cord injury
15. Acute spinal cord injuries and the incidence of clinically occurring thromboembolic disease
16. Is chronic spinal cord injury associated with increased risk of venous thromboembolism?
17. Causes of death in the early and late stages of paraplegia
18. Causes of death during the first 12 years after spinal cord injury
19. Experience with the management of thrombo-embolism in patients with spinal cord injury. Part 1: Incidence, diagnosis and role of some risk factors
20. Anticoagulant therapy in patients with spinal cord injury
21. Venous thrombosis and pulmonary embolism in spinal cord injury
22. Clinical practice guidelines: Spinal cord medicine consortium
23. Prevention of venous thromboembolism
24. Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence)
25. Prophylaxis of deep venous thrombosis and pulmonary embolisms: Current recommendations
26. Tinzaparin - A once-daily low-molecular-weight heparin for the treatment of deep vein thrombosis
27. Clinical economics: A guide to the economic analysis of clinical practices
28. Cost-effectiveness analysis
29. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: Decision and cost-effectiveness analyses
30. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty
31. Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery
32. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin: An economic perspective
33. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: An economic perspective
34. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A cost-effectiveness analysis
35. Sensitivity analysis
36. Prevention of thromboembolism in spinal cord injury: Role of low molecular weight heparin
37. Enoxaparin for thromboembolism prophylaxis in spinal injury: Preliminary report on experience with 105 patients
38. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
39. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in low extremity arthroplasty: A cohort study of 1,984 patients
40. A comparison of intermittent calf compression and enoxaparin or thromboprophylaxis in total hip replacement: A pilot study
41. A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement
42. Prevention of deep vein thrombosis after elective hip surgery: A randomized trial comparing low molecular weight heparin with standard unfractionated heparin
43. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: A clinical trial comparing efficacy and safety
44. Prevention of thromboembolism in 190 hip arthroplasties: Comparison of LMW heparin and placebo
45. Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement
46. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty: A prospective randomized study
47. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: The French Study - Venographic outcomes at 35 days
48. Deep vein thrombosis prophylaxis in the outpatient setting: Preventing complications following hospital discharge
49. The post-discharge prophylactic management of the orthopedic patient with low-molecular weight heparin: Enoxaparin
50. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
51. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish prolonged prophylaxis (DaPP) study
52. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
53. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin)
54. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison
55. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting
56. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin
57. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection
58. UK patients with deep-vein thrombosis can be safely treated as out-patients
59. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis
60. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin administered at home for deep-vein thrombosis
61. Clinical outcome and cost of hospital vs home treatment of proximal vein thrombosis with a low-molecular-weight heparin: The Vascular Midi-Pyrenees study
62. Eligibility for home treatment of deep vein thrombosis: Prospective study